Chris Ryan

Influencer marketing rates are escalating due to a negotiation ritual where brands consistently push for discounts. This teaches creators to inflate initial quotes, creating a self-perpetuating cycle of unnecessary back-and-forth, similar to healthcare's "chargemaster" system. Brands then lament these inflated prices, which they inadvertently caused. To break this inefficient pattern, brands should proactively disclose their budget range early in discussions. This transparency allows for genuine negotiation on deliverables and scope, leading to fairer, faster deals and stronger partnerships, rather than a guessing game that ultimately drives up costs. Avoiding represented talent or hindering communication only exacerbates the issue.

Here's why influencer rates are artificially high.

Key Takeaways CTGTAC supported interpretability and clinical relevance of ORR/DOR from a single-arm dataset, despite prior CRLs challenging adequacy of evidence and component contribution in a heterogeneous population. IGNYTE anti–PD-1–refractory cohort used intratumoral RP1 (1×10^6 then 1×10^7 PFU/mL) with nivolumab, yielding 33.6% ORR, 16.4% CR, and median DOR 24.8 months. FDA analyses excluding patients with all target lesions injected or no baseline targets reduced ORR to 15.7%; a sensitivity-evaluable set (n=89) showed ORR 24.7%, underscoring RECIST limitations for local therapies. Additional FDA criticisms included reinjection beyond progression, biopsy/surgery effects, retrospective histology and IRC implementation, and non-evaluable assessments, all potentially inflating response metrics and biasing OS interpretation. Safety profile featured 97.9% any-grade TEAEs, 31.4% grade ≥3, 35.7% serious AEs, and 8.6% TEAE-related deaths; AESIs included tumor hemorrhage, sepsis, and capillary leak syndrome. SHOW MORE

Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.

Cevostamab in R/R Multiple Myeloma: Key Highlights In a phase 1 trial, cevostamab monotherapy produced an ORR of 42.1% across all doses and 44.3% at the RP2D.

There is a growing body of information around adolescent neurocognitive development and potential applications to education. In its pure research form, this information is largely inaccessible to educators and educational leaders. The aim of this article is to help translate that information into knowledge that can be applied to schools and education programs. We have built on the literature from the fields of psychology and neuroscience to develop a school review tool. This tool will allow educators to examine their programs and reflect on where their culture and practices align with the neuroscience literature. As a field test, the review tool was applied to two programs and their results shared in this article.

Key Takeaways Accelerated approval covers RP1 plus nivolumab for unresectable advanced cutaneous melanoma with progression on prior PD-1–blocking antibody–based therapy. Regulatory trajectory included two complete response letters before a third BLA acceptance in June 2026. CTGTAC voted 10–3 that IGNYTE efficacy findings were evaluable and clinically meaningful in the anti–PD-1–pretreated setting. IGNYTE efficacy-evaluable cohort (n=91) achieved ORR 24.2% (95% CI, 15.8%–34.3%) and median DOR 14.1 months (95% CI, 10.7–NR). SHOW MORE

In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.

Key Takeaways Accelerated approval covers R/R multiple myeloma after ≥1 prior line that included both a proteasome inhibitor and an immunomodulatory agent, using the IberDd triplet regimen. EXCALIBER-RRMM demonstrated superior MRD-negative complete response at any time with IberDd versus DVd (41% vs 21%; P<.0001), forming the basis for the regulatory decision. Two-stage design included dose optimization (1.0, 1.3, 1.6 mg iberdomide) before expansion; 1.0 mg was selected using integrated safety, PK, and efficacy data. Stage 2 randomizes ~664 patients 1:1, stratified by prior lines, age, and ISS stage; CD38-antibody–refractory or bortezomib-refractory patients are excluded. Dual primary endpoints are MRD negativity and PFS, with secondary endpoints including OS, ORR, DoR, and HRQoL; PFS follow-up continues after the MRD analysis. SHOW MORE

Earlier CAR T-Cell Therapy in R/R Multiple Myeloma CAR T-cell therapy is approved in earlier lines of therapy for relapsed/refractory multiple myeloma, but real-world use lags behind eligibility.